See Shionogi-Sponsored Publications

Publications

Here, you can review available Shionogi-sponsored publications. If you would like an electronic copy of one of the journal publications on this page, please contact
Shionogi Medical Information for further assistance.

Information about investigational compounds or investigational uses of products does not imply FDA approval of these compounds or uses, nor does it establish the safety or efficacy of these compounds or uses. There is no guarantee that the investigational compounds or investigational uses of products will receive FDA approval. Shionogi does not recommend or suggest use of its products in a manner inconsistent with FDA-approved labeling.

 
Cefiderocol
Review
Gram-negative infection

Antimicrobial snapshot: cefiderocol

Published:
2026
Authors:
Nguyen ST, Simon S, DeJonge BLM.
 
Cefiderocol
Real-world evidence
Gram-negative infection

Cefiderocol activity against multidrug-resistant isolates from the PERSEUS study: relationship between cefiderocol minimum inhibitory concentration and clinical outcomes 

Published:
2026
Authors:
Cantón R, García-Castillo M, Hernández-García M, et al.
 
Ensitrelvir
Pharmacokinetics/Pharmacodynamics
COVID-19

Effects of ensitrelvir on the pharmacokinetics of combined oral contraceptives (ethinyl estradiol/drospirenone) in healthy adult women: a phase 1 fixed-sequence, multiple-dose, drug–drug interaction study

Published:
2026
Authors:
Shimizu R, Shibata RY, Kubota R, et al.
 
Ensitrelvir
Phase 3
COVID-19

Ensitrelvir for COVID-19 postexposure prophylaxis in household contacts 

Published:
2026
Authors:
Hayden FG, Shinkai M, Clark TW, et al.
 
Cefiderocol
In vitro
Gram-negative infection

Understanding mechanisms of reduced cefiderocol susceptibility in pvdS and fecI mutants of Pseudomonas aeruginosa

Published:
2026
Authors:
Yamano Y, Takemura M, Longshaw C, et al.